Leerink Swann Trims Gilead Sciences (GILD) Target Price to $83.00

Gilead Sciences (NASDAQ:GILD) had its price objective reduced by Leerink Swann from $86.00 to $83.00 in a research note issued to investors on Wednesday morning. They currently have a market perform rating on the biopharmaceutical company’s stock.

GILD has been the topic of several other research reports. Vetr cut Gilead Sciences from a buy rating to a hold rating and set a $91.25 price target on the stock. in a research report on Monday, January 29th. Citigroup upgraded Gilead Sciences from a neutral rating to a buy rating and dropped their price target for the company from $88.80 to $76.00 in a research report on Tuesday, January 30th. Bank of America boosted their price target on Gilead Sciences from $82.00 to $87.00 and gave the company a neutral rating in a research report on Wednesday. Morgan Stanley dropped their price target on Gilead Sciences from $87.00 to $84.00 and set an equal weight rating on the stock in a research report on Wednesday. Finally, Barclays restated an overweight rating and issued a $90.00 price target on shares of Gilead Sciences in a research report on Wednesday, October 11th. One equities research analyst has rated the stock with a sell rating, twelve have issued a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the company’s stock. The company presently has an average rating of Buy and an average target price of $86.56.

Shares of Gilead Sciences (NASDAQ GILD) opened at $79.32 on Wednesday. The company has a current ratio of 3.55, a quick ratio of 3.56 and a debt-to-equity ratio of 1.10. Gilead Sciences has a 52-week low of $63.76 and a 52-week high of $89.54. The company has a market capitalization of $103,613.26, a PE ratio of 22.79, a PEG ratio of -1.75 and a beta of 1.22.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 EPS for the quarter, topping the Zacks’ consensus estimate of $1.67 by $0.11. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The business had revenue of $5.95 billion for the quarter, compared to analysts’ expectations of $5.71 billion. During the same quarter in the previous year, the firm earned $2.70 earnings per share. The business’s revenue was down 18.7% compared to the same quarter last year. research analysts forecast that Gilead Sciences will post 6.41 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 29th. Shareholders of record on Friday, March 16th will be given a dividend of $0.57 per share. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.52. The ex-dividend date is Thursday, March 15th. This represents a $2.28 annualized dividend and a yield of 2.87%. Gilead Sciences’s payout ratio is presently 59.77%.

In other Gilead Sciences news, Chairman John C. Martin sold 50,000 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $83.56, for a total transaction of $4,178,000.00. Following the transaction, the chairman now owns 3,046,766 shares in the company, valued at approximately $254,587,766.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider John F. Milligan sold 220,000 shares of the business’s stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $72.88, for a total value of $16,033,600.00. The disclosure for this sale can be found here. Insiders have sold a total of 578,333 shares of company stock worth $44,100,508 in the last quarter. 1.30% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GILD. FMR LLC boosted its stake in shares of Gilead Sciences by 1.1% during the 2nd quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock worth $1,630,581,000 after acquiring an additional 258,005 shares in the last quarter. Macquarie Group Ltd. boosted its stake in shares of Gilead Sciences by 26.6% during the 3rd quarter. Macquarie Group Ltd. now owns 479,332 shares of the biopharmaceutical company’s stock worth $38,836,000 after acquiring an additional 100,741 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Gilead Sciences by 2.4% during the 2nd quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock worth $6,571,355,000 after acquiring an additional 2,148,697 shares in the last quarter. Northern Trust Corp boosted its stake in shares of Gilead Sciences by 0.7% during the 2nd quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock worth $1,162,949,000 after acquiring an additional 116,780 shares in the last quarter. Finally, Toronto Dominion Bank boosted its stake in shares of Gilead Sciences by 19.0% during the 2nd quarter. Toronto Dominion Bank now owns 472,577 shares of the biopharmaceutical company’s stock worth $33,445,000 after acquiring an additional 75,364 shares in the last quarter. Institutional investors own 75.84% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was originally posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this article on another publication, it was copied illegally and republished in violation of United States and international copyright legislation. The original version of this article can be read at https://sportsperspectives.com/2018/02/11/leerink-swann-trims-gilead-sciences-gild-target-price-to-83-00.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply